Annales d'endocrinologie最新文献_第3页

Chapter 10: What parathyroid imaging is required for hyperparathyroidism? 第十章：甲状旁腺功能亢进需要什么样的甲状旁腺显像？

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101699

Benjamin Chevalier , Cécile Ghander , Miriam Ladsous , Sébastien Gaujoux , David Taieb , Camille Buffet , Delphine Drui , Jean-Christophe Lifante , Luigi Maione , Charlotte Lussey-Lepoutre , Françoise Borson-Chazot

{"title":"Chapter 10: What parathyroid imaging is required for hyperparathyroidism?","authors":"Benjamin Chevalier , Cécile Ghander , Miriam Ladsous , Sébastien Gaujoux , David Taieb , Camille Buffet , Delphine Drui , Jean-Christophe Lifante , Luigi Maione , Charlotte Lussey-Lepoutre , Françoise Borson-Chazot","doi":"10.1016/j.ando.2025.101699","DOIUrl":"10.1016/j.ando.2025.101699","url":null,"abstract":"<div><div>In over 80% of cases, primary hyperparathyroidism results from hypersecretion of PTH by a single parathyroid adenoma. Multi-glandular involvement, combining adenoma and/or hyperplasia in varying proportions, is also possible, although less frequent. When the diagnosis of hyperparathyroidism is certain and surgery is envisaged, imaging is useful for locating the hyperfunctioning gland or glands. First-line exploration is based on a parathyroid ultrasound and a nuclear medicine examination, which may be parathyroid scintigraphy, preferably double isotope I/<sup>12399m</sup> Tc-sestamibi, with planar and tomoscintigraphic acquisitions, or a PET-CT scan with <sup>18</sup>F-choline. In the event of negative results, it is advisable to perform a choline PET scan if the initial examination was scintigraphy. In difficult situations, additional investigations using 4D parathyroid CT or parathyroid MRI, fine-needle aspiration cytology and determination of PTH in the flushing fluid are possible after multidisciplinary discussion in an expert center.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 1","pages":"Article 101699"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acknowledging our 2024 reviewers 感谢我们的2024位评审

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101708

引用次数: 0

Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis 第十五章：复发性或持续性原发性甲状旁腺功能亢进。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101704

Miriam Ladsous , Sophie Deguelte , Elif Hindié , Robert Caiazzo , Brigitte Delemer

{"title":"Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis","authors":"Miriam Ladsous , Sophie Deguelte , Elif Hindié , Robert Caiazzo , Brigitte Delemer","doi":"10.1016/j.ando.2025.101704","DOIUrl":"10.1016/j.ando.2025.101704","url":null,"abstract":"<div><div>Persistent primary hyperparathyroidism is defined as the persistence or recurrence of hypercalcemia within 6 months of parathyroid surgery. Recurrent primary hyperparathyroidism is defined as the recurrence of primary hyperparathyroidism more than 6 months after an initially curative parathyroidectomy. In these situations, it is essential to rule out differential diagnoses, and in particular secondary hyperparathyroidism and familial hypocalciuric hypercalcemia. Failure to remove the pathological parathyroid gland or glands during initial surgery for primary hyperparathyroidism is the most common situation in non-expert centers. In other situations, genetically determined multi-glandular primary hyperparathyroidism must be screened for. More rarely, a second sporadic adenoma is identified, or, exceptionally, a parathyroid carcinoma or parathyromatosis. Effective morphological evaluation, combining a morphological and functional imaging, is essential prior to any new parathyroid surgery. The indications for surgery must be discussed in a multidisciplinary team, assessing the risk/benefit ratio, since the risk of surgical complications is higher. Revision surgery should be performed using a suitable approach, after laryngoscopy, in an expert center, ideally with intraoperative PTH measurement and recurrent nerve neuromonitoring.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 1","pages":"Article 101704"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chapter 4: Differential diagnosis of primary hyperparathyroidism 第四章：原发性甲状旁腺功能亢进的鉴别诊断。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101693

Peter Kamenický , Pascal Houillier , Marie-Christine Vantyghem

{"title":"Chapter 4: Differential diagnosis of primary hyperparathyroidism","authors":"Peter Kamenický , Pascal Houillier , Marie-Christine Vantyghem","doi":"10.1016/j.ando.2025.101693","DOIUrl":"10.1016/j.ando.2025.101693","url":null,"abstract":"<div><div>The differential diagnosis of primary hyperparathyroidism can be considered clinically, biologically and radiologically. Clinically, primary hyperparathyroidism should be suspected in case of diffuse pain, renal lithiasis, osteoporosis, repeated fracture, cognitive or psychiatric disorder, or disturbance of consciousness. Nevertheless, the differential diagnosis of primary hyperparathyroidism is mainly biological, particularly in atypical forms, which must be differentiated from hypercalcemia with hypocalciuria or non-elevated PTH on the one hand, and from normo-calcemia with elevated PTH, hypophosphatemia or hypercalciuria on the other. Any differential diagnosis must be preceded by an analysis of the factors likely to disturb phospho-calcium parameters: vitamin D deficiency (assay), renal insufficiency (eGFR measurement), malabsorption (inflammatory disease of the digestive tract, celiac disease, bariatric surgery, etc.), insufficient calcium intake (GRIO questionnaire) and iatrogenic causes (diuretics, anti-osteoporotic drugs, excessive vitamin D or calcium supplementation, lithium, corticosteroid therapy, phosphorus intake). Once these factors have been eliminated, hypercalcemia with hypocalciuria should suggest a genetic cause. Hypercalcemia with non-elevated PTH may be secondary to neoplasm, hypervitaminosis D (excessive intake, production or catabolism), immobilization or endocrine causes. Elevated PTH values without hypercalcemia must be differentiated from normo-calcemic hyperparathyroidism. High PTH levels are found in PTH-resistant patients, as well as in hypophosphatemic (especially X-linked) or hypercalciuric tubulopathies (certain rare diseases, immobilization, loop diuretics or idiopathic causes favored by a metabolic syndrome). Radiologically, brown tumor must be differentiated primarily from bone metastasis, chondrosarcoma and giant cell tumor.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 1","pages":"Article 101693"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor 第八章：侵袭性原发性HPT的处理：甲状旁腺癌和非典型甲状旁腺肿瘤。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101697

Christine Do Cao , Niki Christou , Julien Hadoux , Désirée Deandreis

{"title":"Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor","authors":"Christine Do Cao , Niki Christou , Julien Hadoux , Désirée Deandreis","doi":"10.1016/j.ando.2025.101697","DOIUrl":"10.1016/j.ando.2025.101697","url":null,"abstract":"<div><div>Parathyroid carcinoma is extremely rare, affecting 1% of cases of primary hyperparathyroidism. For this reason, management is poorly codified and requires expertise in specialized center. PC is genetically determined in a quarter to a third of cases, notably involving the <em>CDC73</em> gene coding for parafibromin. Since 2004, malignancy has been diagnosed on both macroscopic and microscopic invasion criteria, as set out in the WHO 2022 histopathological classification. Surgery is an essential part of treatment. Resection must be oncological, after prior medical treatment for hypercalcemia that are often severe, and be supported by imaging studies to guide the surgical procedure. After incomplete resection with no possibility of reoperation, adjuvant external radiotherapy should be discussed, given the high risk of local recurrence, even if its value is debated. The recurrence rate for PC is 30–67%. Overall 5-year survival ranges from 60 to 95%. In cases of localized or oligometastatic recurrence, locoregional treatments are preferred. There is no standard treatment for metastatic disease, but the literature review suggests possible benefit from targeted anti-angiogenic therapy. Extensive tumor genotyping is recommended to screen for targetable alterations in driver genes. All parathyroid carcinoma cases should be reviewed in a specialized tumor board. Patients operated on for atypical parathyroid tumors or parathyroid tumors with loss of immunohistochemical expression of parafibromin also require long-term monitoring.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 1","pages":"Article 101697"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chapter 13: Changes in 2022 WHO classification of parathyroid tumors 第13章：2022 WHO对甲状旁腺肿瘤的分类。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101702

Margot Dupeux , Sébastien Aubert

引用次数: 0

Chapter 9: Indications for the treatment of primary hyperparathyroidism 第九章：治疗指征。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101698

Samuel Frey , Helena Mosbah , Gianluca Donatini , Laurent Brunaud , Olivier Chabre , Delphine Vezzosi

引用次数: 0

Epidemiology of primary hyperparathyroidism (Chapter 1) 第一章：原发性甲状旁腺功能亢进的流行病学。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101690

Thomas Cuny , Muriel Mathonnet , Igor Tauveron

引用次数: 0

Chapter 6: Syndromic primary hyperparathyroidism 第六章：原发性甲状旁腺功能亢进综合征。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2025.101695

Abdallah Al-Salameh , Magalie Haissaguerre , Christophe Tresallet , Paulina Kuczma , Camille Marciniak , Catherine Cardot-Bauters

{"title":"Chapter 6: Syndromic primary hyperparathyroidism","authors":"Abdallah Al-Salameh , Magalie Haissaguerre , Christophe Tresallet , Paulina Kuczma , Camille Marciniak , Catherine Cardot-Bauters","doi":"10.1016/j.ando.2025.101695","DOIUrl":"10.1016/j.ando.2025.101695","url":null,"abstract":"<div><div>Syndromic primary hyperparathyroidism has several features in common: younger age at diagnosis when compared with sporadic primary hyperparathyroidism, often synchronous or metachronous multi-glandular involvement, higher possibility of recurrence, association with other endocrine or extra-endocrine disorders, and suggestive family background with autosomal dominant inheritance. Hyperparathyroidism in multiple endocrine neoplasia type 1 is the most common syndromic hyperparathyroidism. It is often asymptomatic in adolescents and young adults, but may be responsible for recurrent lithiasis and/or bone loss. Hyperparathyroidism-jaw tumor syndrome is less frequent, but often immediately symptomatic, with higher blood calcium levels, and is sometimes associated with an atypic parathyroid tumor or parathyroid carcinoma. Hyperparathyroidism in multiple endocrine neoplasia type 2A is not at the forefront of the clinical picture, rarely revealing the disease, and often manifests with few symptoms. Multiple endocrine neoplasia type 4 is a more recently described entity, in which hyperparathyroidism seems to occur later and be less severe than in previous syndromes. In all cases, the indications and modalities of surgical treatment should be discussed in an expert center. The risk of recurrence after surgery, particularly high in multiple endocrine neoplasia type 1, requires long-term monitoring.</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 1","pages":"Article 101695"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of children and adult craniopharyngiomas: A French Endocrine Society/French Society for Paediatric Endocrinology & Diabetes Consensus Statement 儿童和成人颅咽管瘤的诊断与管理：法国内分泌学会/法国儿科内分泌与糖尿病学会共识声明。

IF 2.9 3区医学

Annales d'endocrinologie Pub Date : 2025-02-01 DOI: 10.1016/j.ando.2024.07.002

Thomas Cuny , Rachel Reynaud , Gérald Raverot , Régis Coutant , Philippe Chanson , Dulanjalee Kariyawasam , Christine Poitou , Cécile Thomas-Teinturier , Bertrand Baussart , Dinane Samara-Boustani , Loïc Feuvret , Carine Villanueva , Chiara Villa , Benjamin Bouillet , Maïthé Tauber , Stéphanie Espiard , Sarah Castets , Albert Beckers , Jessica Amsellem , Marie-Christine Vantyghem , Blandine Gatta-Cherifi

引用次数: 0